Showing results (251-260 of 358) with videos related to

Sort By:
Pageof 36
NPJ Breast Cancer|June 21, 2025
A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancerJessica Mezzanotte-Sharpe, Brandie C Taylor, Paula I Gonzalez-Ericsson, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|August 12, 2024
Treatment Responses in Histologic Versus Molecular Diagnoses of Lung RejectionA Zajacova, M Mackova, K Halloran, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|December 6, 2024
Elevated PD-L1 and PECAM-1 as Diagnostic Biomarkers of Acute Rejection in Lung TransplantationRene Novysedlak, Jan Balko, Janis Tavandzis, et al.
Oncoimmunology|May 17, 2017
Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profilingPeter J Siska, Romany A N Johnpulle, Alice Zhou, et al.
The Lancet. Oncology|November 17, 2018
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance studyJoe-Elie Salem, Ali Manouchehri, Melissa Moey, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 14, 2013
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapiesAriella B Hanker, Adam D Pfefferle, Justin M Balko, et al.
Oncogene|October 7, 2014
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancerL M Dillon, J R Bean, W Yang, et al.
Bioorganic & Medicinal Chemistry Letters|October 29, 2015
Discovery of an orally bioavailable isoxazoline benzoxaborole (AN8030) as a long acting animal ectoparasiticideYong-Kang Zhang, Jacob J Plattner, Eric E Easom, et al.
The Oncologist|August 14, 2021
Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer CenterNeha M Jain, Lauren Schmalz, Christopher Cann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2017
<i>PIK3CA</i> C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K<b>α</b> InhibitorsSarah Croessmann, Jonathan H Sheehan, Kyung-Min Lee, et al.
Pageof 36